BeiGene is a life sciences, biotechnology company.
BeiGene is a global biotechnology company that is discovering and developing innovative oncology medicines that are more accessible and affordable to patients worldwide. The company is expediting development of its broad and diverse pipeline of novel therapeutics through its internal capabilities and collaborations to fulfill its commitment to radically improving access to medicines for more patients who need them. BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 60 countries as a treatment for blood cancers.BeiGene was founded in 2010 and has grown to more than 9,000 colleagues across the globe, one of the largest oncology research teams in the world. The Company has administrative offices on three continents, including in Cambridge, MA.BeiGene’s pipeline of cancer therapeutics includes both small molecules and biologics targeting a wide range of cancer types and stages, including hematologic malignancies and solid tumors. To most efficiently advance its pipeline of innovative medicines, BeiGene has built extensive internal clinical development capabilities. The company is rapidly expanding its in-house manufacturing capabilities to support an agile and responsive network to deliver its medicines to the patients who need them.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 12, 2020 | Post-IPO Equity | $2.08B | 3 | Hillhouse Capital Group | — | Detail |
Oct 31, 2019 | Post-IPO Equity | $2.70B | 1 | Amgen | — | Detail |
Aug 2, 2018 | Post-IPO Secondary | $0.90B | — | — | — | Detail |
Jan 19, 2018 | Post-IPO Equity | $750M | — | — | — | Detail |
Nov 27, 2016 | Post-IPO Equity | $185M | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 2, 2021
Shoreline Biosciences
|
Series B | $140M | Biotechnology | — |
Jun 23, 2021
Strand Therapeutics
|
Series A | $52M | Biotechnology | — |
Mar 17, 2021
Boston Immune Technologies & Therapeutics
|
Series A | $10M | Biotechnology | Yes |
Jan 3, 2020
Leap Therapeutics
|
Post-IPO Equity | $27M | Biotechnology | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hillhouse Capital Group | Yes | Post-IPO Equity |
Amgen | Yes | Post-IPO Equity |
CITIC Capital Holdings | Yes | Series A |
Amgen Ventures | — | Post-IPO Equity |
GIC | — | Post-IPO Equity |
Rock Springs Capital | — | Series B |
T. Rowe Price | — | Series B |
BeiGene has had 1 exits. BeiGene most notable exits include Leap Therapeutics
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Jan 27, 2017 | Leap Therapeutics | IPO | Biotechnology | Detail |